Improving Prognostication in Colon Cancer

Starting soon

Conditions studied: Colon Cancer, Colon Adenocarcinoma

In brief

The goal of this study is to test better ways to predict if cancer will return after surgery in adults (18+) who have been diagnosed with stage II or III colon cancer. The main questions it aims to answer are: * Can computer programs (Artificial Intelligence) and special blood tests give more accurate information about the risk of cancer returning than the methods doctors use today? * Does combining these new tests help doctors better understand which patients really need chemotherapy and which do not? Researchers will compare the new computer and blood tests to the standard hospital methods used now to see if the new way is more accurate in predicting the cancer's behavior Participants will: * Sign a form saying they agree to take part in the study * Have their standard surgery to remove the tumor * Give a few extra teaspoons of blood during their regular, scheduled hospital visits * Allow researchers to scan and study a small piece of the tumor that was already removed during surgery * Continue with their normal hospital check-ups for up to five years so researchers can track their health

Key facts

Study ID

NCT07673393

Run by

Universitaire Ziekenhuizen KU Leuven

People needed

400

Starts

2026-09-01

Expected to finish

2033-09-01

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
• Male and female participants, at least 18 years of age at the time of signing the Informed Consent Form (ICF).
• Newly diagnosed primary colon tumor clinically and/or histologically consistent with localized colon adenocarcinoma and planned for curative-intent surgical resection.
• Clinical stage compatible with non-metastatic disease at time of screening and considered eligible for standard curative-intent management according to investigator assessment.
• WHO (ECOG) performance status ≤ 3 at baseline.

You may not qualify if…

• Participant has been diagnosed with metastatic disease (Stage IV)
• Participant has been diagnosed with rectal cancer
• Participant has been diagnosed with synchronous primary colon tumors (i.e., presence of two or more primary colon tumors detected simultaneously at diagnosis)
• Participant has received prior systemic therapy (chemotherapy, targeted therapy, immunotherapy, or radiotherapy) for colon cancer
• Participation in an interventional Study with an investigational medicinal product (IMP) or device within 30 days prior to inclusion.
• Participant had prior history of colon cancer requiring systemic treatment or major colorectal oncologic surgery.
• Any severe, uncontrolled, or life-threatening medical condition that, in the opinion of the investigator, could interfere with study participation, interpretation of study assessments, or pose excessive risk to the participant (e.g. severe cardiac, hepatic, renal, or uncontrolled infectious disease).

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.